Adimab team ac­cus­es promi­nent MIT in­ves­ti­ga­tor Ram Sasisekha­ran of rip­ping off an­ti­bod­ies and pre­sent­ing them as his own

Dart­mouth pro­fes­sor and long­time Adimab chief Till­man Gern­gross is call­ing out not­ed MIT in­ves­ti­ga­tor Ram Sasisekha­ran for rip­ping off the work of oth­ers in the an­ti­body field and pass­ing it off as his own “ex­tra­or­di­nary” de­sign done in sil­i­co. And one of those an­ti­bod­ies was at the cen­ter of a re­cent $430 mil­lion buy­out.

“We as­sem­bled the facts, we checked the facts with the lead­ing an­ti­body ex­perts out­side of Adimab and they all agreed with us,” Gern­gross tells me. “If you look at the facts it looks like se­ri­ous mis­con­duct.”

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.